Faron Pharmaceuticals Oy (HEL:FARON)

Market Cap	59.63M -73.9%
Revenue (ttm)	n/a
Net Income	-27.26M
EPS	-0.24
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	722,021
Average Volume	1,137,590
Open	0.5250
Previous Close	0.5220
Day's Range	0.5140 - 0.5340
52-Week Range	0.4915 - 3.3450
Beta	1.09
RSI	29.03
Earnings Date	Mar 4, 2026

About Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company’s lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. It is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 32
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: FARON